Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension

Safety, Tolerability and Efficacy of Micardis® (Telmisartan) in Patients With Essential Hypertension

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02176850

Enrollment

19870

Registered

2014-06-27

Start date

1999-01-31

Completion date

Unknown

Last updated

2014-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

This post-marketing surveillance study was designed to supplement under conditions of normal clinical practice the data on the safety, tolerability and efficacy of Micardis® collected during the clinical studies.

Interventions

DRUGMicardis®

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients of both sexes with essential hypertension and a minimum age of 18 years

Exclusion criteria

(Not applicable)

Design outcomes

Primary

Measure	Time frame
Indicence of ulcera	Up to 6 months after start of study
Incidence of gastrointestinal (GI) bleedings	Up to 6 months after start of study

Secondary

Measure	Time frame	Description
Incidence of adverse events (GI-complaints inclusive)	Up to 6 months after start of study	—
Change from baseline in office blood pressure	Up to 6 months after start of study	—
Response rate	Up to 6 months after start of study	full response: reduction of diastolic blood pressure (DBP) by \>= 10 mmHg or final DBP \<= 90 mmHg overall response: reduction of DBP by \>= 7mmHg or final DBP \<= 90 mmHg

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026